Alpha-fetoprotein in abortion

Area of Science:

• Obstetrics and Gynecology
• Maternal-Fetal Medicine
• Biochemistry

Background:

• Threatened abortion poses a significant clinical challenge.
• Accurate prediction of abortion outcomes is crucial for patient management.
• Maternal serum alpha-fetoprotein (AFP) is a biomarker with potential prognostic value.

Purpose of the Study:

• To assess the clinical utility of maternal serum alpha-fetoprotein (AFP) in predicting the outcome of threatened abortion.
• To investigate the correlation between AFP levels and specific abortion complications.

Main Methods:

• Prospective assessment of maternal serum alpha-fetoprotein (AFP) levels in women with threatened abortion.
• Correlation of AFP concentrations with pregnancy outcomes, including spontaneous abortion, blighted ovum, and intrauterine fetal death.
• Analysis of AFP levels in postabortion samples following instrumental or prostaglandin-induced abortions.

Main Results:

• Women with abnormal serum AFP levels after 13 weeks of gestation experienced a higher frequency of abortion (10/12) compared to those with normal levels (2/12).
• Low maternal serum AFP concentrations were associated with blighted ovum.
• High maternal serum AFP concentrations were linked to intrauterine fetal death.
• Postabortion serum AFP levels were frequently elevated compared to preabortion levels, regardless of the abortion method.

Conclusions:

• Maternal serum alpha-fetoprotein (AFP) levels offer a novel method for predicting the outcome of threatened abortion.
• AFP testing can aid in differentiating between various complications of early pregnancy loss.
• Monitoring AFP levels may improve the clinical management of threatened abortions.